DHDaniel Heinzelmann

Daniel Heinzelmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Heinzelmann has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Benjamin Renner

    Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach, Germany

    4 shared publications
  • Patrick Schulz

    Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach, Germany

    4 shared publications
  • Franziska Reuss

    Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach, Germany

    3 shared publications
  • Benjamin Lindner

    Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach, Germany

    2 shared publications
  • Benjamin Lindner

    Bioprocess Development Biologicals Cell Line Development Boehringer Ingelheim GmbH & Co. KG Biberach Germany

    2 shared publications
  • Emely Walker

    Development Core Technologies, Viral Therapeutics Center, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach, Germany

    2 shared publications

Latest Publications

  • Open Access

    Discovery of a chimeric transposase-transposon system for advanced genome engineering

    by Daniel Heinzelmann, Franziska Reuss, Nikolas Zeh, Robin Nilson, Emely Walker, Juergen Fieder, Benjamin Lindner, Benjamin Renner, Patrick Schulz, Simon Fischer, et al.


  • Open Access

    Discovery of a Novel Chimeric Transposase-Transposon System for Advanced Genome Engineering

    by Daniel Heinzelmann, Franziska Reuss, Nikolas Zeh, Robin Nilson, Emely Walker, Juergen Fieder, Benjamin Lindner, Benjamin Renner, Patrick Schulz, Simon Fischer, et al.

    Summary: Transposases revolutionized the field of genetic engineering, yet the scarcity of functional systems remains a challenge. In response, we conducted a metagenomic screening and identified a novel transposase system from Acyrthosiphon pisum . Through systematic optimization, we enhanced nuclear localization, transposon composition, and created a hyperactive transposase variant to boost transposition efficiency. Intriguingly, the combined application of the newly discovered transposase with inverted terminal repeat sequences from a related pea aphid species, Aphis craccivora , further enhanced transposition activity, resulting in the first chimeric transposase system reported so far. We investigated the genomic integration events following transposition in mammalian cells, to understand the underlying mechanisms and optimize the efficiency of transgene integration. This optimized system can expedite the generation of recombinant protein producing CHO cell lines, even surpassing the hyperactive piggyBac system with regards to cell specific productivity. These findings introduce a significant addition to the field of semi-targeted transgene integration technologies, offering substantial potential for enhancing biologics manufacturing.

  • Open Access

    Bacterial Glutamine Synthetases as a Novel Metabolic Selection Marker to Improve CHO Cell Culture Performance Through Selection Stringency Modulation

    by Daniel Heinzelmann, Nicholas Michelarakis, Franziska Reuss, Benjamin Lindner, Anne R. Karow‐Zwick, Joschka Bauer, Benjamin Renner, Simon Fischer, Patrick Schulz, Moritz Schmidt

    The use of metabolic selection markers has advanced stable cell line generation, increasing productivity while simultaneously eliminating the need for antibiotic reagents. This study explores the potential of bacterially derived glutamine synthetases (GS) as a novel generation of metabolic selection markers to further enhance CHO cell culture performance. GS‐I proteins were extracted from the genomes of enterobacterial and actinomycetes species. Three of these enzymes demonstrated functionality when stably transfected into GS‐deficient CHO cells, leading to a 3‐ to 4‐fold increase in antibody titer compared to endogenous GS from Cricetulus griseus. This study indicates that the functionality of bacterial GS enzymes in mammalian cells is determined by solvent accessibility and the geometry of the catalytic binding pocket. Dysfunctional variants showed a less accessible bifunnel. Bacterial GS were evaluated for their bioprocess performance leading to superior stable pool and clone performance. Transcriptome analysis further revealed that regulatory cellular mechanisms were decoupled in a cross‐species set‐up, reinforcing the suitability of repurposing bacterial enzymes as selection markers in mammalian cell lines. By modulating the selection stringency, an increase in expression performance was achieved without impairing the bioprocess behavior or long‐term cell line stability.


  • Open Access

    Droplet digital PCR: A comprehensive tool for genetic analysis and prediction of bispecific antibody assembly during cell line development

    by Daniel Heinzelmann, Benjamin Lindner, Benjamin Renner, Simon Fischer, Patrick Schulz, Moritz Schmidt